
    
      Multi-center, open-label, dose-escalation, phase 1/2a, safety and tolerability study to
      evaluate three dose groups of suprachoroidally administered CLS-AX following intravitreal
      anti-VEGF therapy in subjects with neovascular age-related macular degeneration
    
  